Yibo Meng
Overview
Explore the profile of Yibo Meng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
19
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhou C, Zhang X, Ma H, Zhou Y, Meng Y, Chen C, et al.
BMC Urol
. 2024 Feb;
24(1):32.
PMID: 38321455
Background: USP54, a ubiquitin-specific protease in the deubiquitinase (DUB) family, facilitates the malignant progression of several types of cancer. However, the role of USP54 in prostate cancer (PCa), especially castration-resistant...
2.
Zhang L, Guo H, Zhang X, Wang L, Wei F, Zhao Y, et al.
Funct Integr Genomics
. 2024 Jan;
24(1):21.
PMID: 38286903
No abstract available.
3.
Zhou C, Ma H, Yu W, Zhou Y, Zhang X, Meng Y, et al.
Biochem Biophys Res Commun
. 2024 Jan;
698:149543.
PMID: 38266312
ANP32B is a histone chaperone that interacts with various transcription factors that regulate cancer cell proliferation, immigration, and apoptosis. c-Myc, a well-known oncogenic protein, is a principal player in the...
4.
Zhang L, Guo H, Zhang X, Wang L, Wei F, Zhao Y, et al.
Funct Integr Genomics
. 2024 Jan;
24(1):15.
PMID: 38240925
Chronic psoriasis is a kind of immune-mediated skin illness and the underlying molecular mechanisms of pathogenesis remain incompletely understood. Here, we used small RNA microarray assays to scan the differential...
5.
Xiao X, Zou J, Fang Y, Meng Y, Xiao C, Fu J, et al.
BMC Complement Altern Med
. 2018 Mar;
18(1):91.
PMID: 29544480
Background: The anti-tumor activities of Natural compounds and their derivatives are of great interest to pharmaceutical industries. Fisetin is one of prospective natural compounds in this regard but unfortunately with...